Last reviewed · How we verify
Seretide 250/placebo via Synchro-Breathe
Seretide combines fluticasone propionate (inhaled corticosteroid) and salmeterol (long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation.
Seretide combines fluticasone propionate (inhaled corticosteroid) and salmeterol (long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | Seretide 250/placebo via Synchro-Breathe |
|---|---|
| Also known as | Advair |
| Sponsor | Brian J Lipworth |
| Drug class | Combination inhaled corticosteroid and long-acting beta-2 agonist (ICS/LABA) |
| Target | Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Fluticasone propionate suppresses inflammatory responses in the airways by binding glucocorticoid receptors, reducing mucus production and airway edema. Salmeterol activates beta-2 adrenergic receptors on bronchial smooth muscle, causing sustained bronchodilation. Together, they provide both anti-inflammatory and bronchodilatory effects for maintenance asthma and COPD control.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Nervousness/anxiety
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Seretide 250/placebo via Synchro-Breathe CI brief — competitive landscape report
- Seretide 250/placebo via Synchro-Breathe updates RSS · CI watch RSS
- Brian J Lipworth portfolio CI